Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI).